-
Mashup Score: 0PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC - 6 hour(s) ago
The biomarker analysis of patients enrolled on part B of the CheckMate 914 trial explored the effects of PD-L1 and KIM-1 expression.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC - 8 day(s) ago
The biomarker analysis of patients enrolled on part B of the CheckMate 914 trial explored the effects of PD-L1 and KIM-1 expression.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC @VincentWenxinXu @danafarber @harvardmed @SITCancer #SITC2024 #kcsm #oncology https://t.co/QFCZBJkYXC
-
PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC @VincentWenxinXu @danafarber @harvardmed @SITCancer #SITC2024 #kcsm #oncology https://t.co/QFCZBJkYXC